TrialESMO open2025

The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

K Verkerk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.